There have been a number of notable updates to have come out of the 2025 ASCO Annual Assembly throughout the realm of hematologic malignancies, like for these with polycythemia vera or a blastic plasmacytoid dendritic cell neoplasm, based on Dr. Raajit Ok. Rampal, who sat down for a post-meeting interview with Dr. Joshua Ok. Sabari.
In the course of the interview, Rampal started by strolling by way of a plenary session which highlighted using rusfertide in sufferers with polycythemia vera, a kind of myeloproliferative neoplasm (blood most cancers) which is characterised by an elevation of the purple blood cells. Within the presentation, investigators shared that the investigative therapeutic allowed sufferers who have been handled to keep away from phlebotomies and expertise symptomatic enchancment. Subsequently, Rampal defined, that these outcomes place rusfertide as a possible remedy for sufferers and is pending regulatory approval.
To study extra about using rusfertide in sufferers with polycythemia vera, and the current ASCO 2025 information, tune into our dialog with Dr. Aaron Gerds, who walked us by way of these findings.
One other subject highlighted by the pair targeted on a examine in important thrombocythemia. The examine in query evaluated ropeginterferon alfa-2b, which is an already-approved agent for sufferers with polycythemia vera, with customary important thrombocythemia remedy. Information to have come out of this examine demonstrated that ropeginterferon led to lowered thrombotic threat, improved symptom management, in addition to decreased driver mutation burden.
Sabari concluded by thanking Rampal for his insights. He stated: “Yeah, fairly spectacular. You understand, it is fascinating that hematologic malignancies are really an amalgamation of many illnesses. Thanks for summarizing that so eloquently. I respect you being right here and thanks for all of the work you do with CURE and for our readers.”
Rampal is the director of the Middle for Hematologic Malignancies, in addition to the director of the Myeloproliferative Neoplasms Program at Memorial Sloan Kettering Most cancers Middle, positioned in New York. Sabari is the editor in chief of CURE. He additionally serves as an assistant professor within the Division of Drugs at NYU Grossman College of Drugs and director of Excessive Reliability Group Initiatives at Perlmutter Most cancers Middle, additionally positioned in New York.
For extra information on most cancers updates, analysis and schooling, don’t neglect to subscribe to CURE®’s newsletters right here.
